H.R. 8908, Generic Drug Acceleration / Petition Restriction. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
H.R. 8908 · Mixed
What it does
This bill amends FDA drug-approval rules to make it easier for the FDA to reject petitions that appear designed primarily to delay generic or biosimilar drug approvals. It tightens the timeline for filing such petitions (60 days from when information became known), gives the FDA explicit authority to deny delay-tactic petitions based on factors like late submission, serial filings, or lack of supporting data, and requires the FDA to report to Congress on petition activity and any delays caused. The bill also bars citizens from suing the FDA over drug approvals unless they first exhaust the petition process and meet strict timing rules.
The analysis names generic drug manufacturers — and 2 more groups — among the beneficiaries.
The trade-off
The bill empowers the FDA to deny petitions based on subjective factors (e.g., 'unreasonable length of time,' 'close in time to patent expiration') without defining 'unreasonable' or 'close,' creating discretion that could be applied to suppress legitimate scientific objections.
The analysis put a high warning level on this bill. Transparency scores 65%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Eric Sorensen. Cosponsored by Stephanie Bice.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.